SCHEMBL17808773

SCHEMBL17808773

O=c1c(-c2ccc3c(c2)OCO3)cnc2c(O)cccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAPDH P04406 1/20 0.47
▸ BCL2L1 Q07817 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ KDR P35968 2/20 0.41
▸ GAA P10253 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ALOX15 P16050 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ HSP90AB1 P08238 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ NPY1R P25929 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17808838 0.78 FYN (0.45) KDM4EKDRGAAMAPTTSHR
SCHEMBL3236843 0.76 RAB9A (0.45) KDM4ERAB9AGAAMAPTMAPK1
SCHEMBL10027278 0.76 MEN1 (0.38) KDM4ERAB9AGAAMAPK1HSD17B10
SCHEMBL17808806 0.74 SMN1; SMN2 (0.73) KDM4EMAPTTSHRMAPK1HSD17B10
SCHEMBL24345099 0.72 RET (0.40) KDM4ERAB9AKDRGAAMAPT
SCHEMBL24344399 0.70 GRM2 (0.38) RAB9AKDRMAPTTSHRMAPK1
SCHEMBL27466656 0.69 BCL2L1 (0.59) GAPDHBCL2L1KDM4ERAB9AMAPT
SCHEMBL18584471 0.67 FYN (0.49) KDM4ERAB9AMAPTTSHRSMN1; SMN2
SCHEMBL10027225 0.67 LMNA (0.43) KDM4EGAAMAPTHSD17B10LMNA
SCHEMBL13313511 0.67 ALDH1A1 (0.49) KDM4ERAB9AGAAMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227292-B1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS ALTERITY THERAPEUTICS LTD (AU) 2022-03-09 — — EP disclosed
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2021-07-29 — — US disclosed
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2021-05-18 — — US disclosed
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2020-10-08 — — US disclosed
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2020-08-11 — — US disclosed
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2019-11-21 — — US disclosed
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2019-05-14 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
WO-2016086261-A1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2016-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO GAPDH 1859/4885BCL2L1 3862/4885KDM4E 2827/4885
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO GAPDH 1859/4885BCL2L1 3862/4885KDM4E 2827/4885
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO GAPDH 1859/4885BCL2L1 3862/4885KDM4E 2827/4885
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO GAPDH 1859/4885BCL2L1 3862/4885KDM4E 2827/4885
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO GAPDH 1859/4885BCL2L1 3862/4885KDM4E 2827/4885
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO GAPDH 1859/4885BCL2L1 3862/4885KDM4E 2827/4885
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO GAPDH 1859/4885BCL2L1 3862/4885KDM4E 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback